2,669 Shares in Natera, Inc. $NTRA Acquired by Magnetar Financial LLC

Key Points

• Magnetar Financial LLC purchased 2,669 shares of Natera, Inc., worth approximately $377,000, marking their new position in the company during the first quarter.
• Insider trading activities included sales by CEO Steven Leonard Chapman, who sold 6,092 shares for over $851,000, reducing his ownership stake by 3.47%.
• Natera reported quarterly earnings of ($0.74) EPS, missing estimates, but showed a 32.2% increase in revenue year-over-year.

Magnetar Financial LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,669 shares of the medical research company's stock, valued at approximately $377,000.

Other hedge funds have also made changes to their positions in the company. LRI Investments LLC bought a new stake in Natera during the 4th quarter valued at $29,000. Bank of Jackson Hole Trust bought a new stake in Natera during the 1st quarter valued at $29,000. Rakuten Securities Inc. raised its stake in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in Natera during the 1st quarter valued at $32,000. Finally, TCTC Holdings LLC raised its stake in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Trading Up 0.9%

Shares of NASDAQ NTRA traded up $1.46 during mid-day trading on Friday, reaching $168.02. The company had a trading volume of 776,006 shares, compared to its average volume of 1,211,789. The stock has a market cap of $23.06 billion, a PE ratio of -87.97 and a beta of 1.68. The company has a 50-day moving average price of $154.35 and a two-hundred day moving average price of $153.91. Natera, Inc. has a 1-year low of $110.57 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. The business's revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the topic of several recent analyst reports. Evercore ISI raised Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. Piper Sandler reiterated an "overweight" rating and set a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a research report on Tuesday. Stephens reiterated an "overweight" rating and set a $183.00 price target on shares of Natera in a research report on Friday, August 15th. Finally, Cowen reiterated a "buy" rating on shares of Natera in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $194.00.

Insider Activity

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director owned 6,015 shares of the company's stock, valued at $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the completion of the sale, the insider directly owned 120,859 shares of the company's stock, valued at $20,137,526.58. This represents a 2.42% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 55,344 shares of company stock valued at $8,271,610. 5.63% of the stock is currently owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.